Is Methylene blue worth it?
Methylene blue is not a normal supplement; it is a pharmacologically active dye-drug being repackaged as a nootropic. A small human imaging study makes it scientifically interesting, but that does not establish a safe daily cognition or longevity routine. The serotonergic drug interaction risk is real enough that casual self-experimentation is the wrong default.
The call
The best healthy-human nootropic evidence is a small randomized imaging study showing acute changes in brain activity and memory retrieval after low-dose methylene blue. That is a signal, not a consumer verdict: it does not prove durable cognitive benefit, daily-use safety, or longevity effects. Reviews of neuropsychiatric use describe heterogeneous clinical experiments rather than a settled supplement indication. Because methylene blue can inhibit MAO-A and interact dangerously with serotonergic drugs, the evidence-to-risk balance is not favorable for casual nootropic use.
Safety
Avoid methylene blue with SSRIs, SNRIs, MAOIs, tricyclics, linezolid, serotonergic migraine drugs, tramadol, meperidine, dextromethorphan, MDMA, stimulant stacks, or other serotonergic agents unless a physician explicitly manages the interaction risk. Avoid with G6PD deficiency, significant anemia, severe kidney disease, pregnancy, breastfeeding, bipolar-spectrum illness, uncontrolled hypertension, or planned surgery. Side effects can include nausea, vomiting, abdominal pain, headache, dizziness, confusion, fever, high blood pressure, chest discomfort, blue-green urine, skin staining, and hemolysis in susceptible people. Non-pharmaceutical dyes, aquarium products, and products without purity testing should not be ingested.
Dose that matters: -; no responsible nonprescription nootropic dose. Human research has tested low-dose oral methylene blue in controlled settings, while approved medical use is drug-directed; retail drops, aquarium products, and compounding-grade claims should not be treated as equivalent to a validated supplement protocol.
Sources
Tier 2 · evidence synthesis · Reviewed by the Stack-kit desk